The stock has experienced significant volatility over the past six months, rallying strongly from around $19 in early October 2025 to a peak near $30 in mid-December, representing a gain of over 42.7%. However, it has since retreated and consolidated, with the current price of $27.46 representing a decline of approximately 4.7% over the last three months and 2.5% over the past month. The current price sits near the middle of its 52-week range of $7.52 to $30.00, indicating it is not at an extreme high or low. The stock has shown relative strength against the S&P 500 over the past month, gaining 2.73% on a relative basis.

Revenue for Q4 2025 was $9.46 billion, representing a year-over-year decline of 5.65%. Profitability remains challenged, with the company reporting a net loss of $252 million for the quarter, translating to a net margin of -2.66%. Financial health shows a debt-to-equity ratio of 0.91, indicating a moderate level of leverage, but the current ratio of 1.06 suggests adequate short-term liquidity. The company generated positive free cash flow of $1.38 billion in Q4, and trailing twelve-month free cash flow stands at $3.09 billion. Operational efficiency metrics are weak, with a Return on Equity (ROE) of 2.02% and a Return on Assets (ROA) of 1.02%, indicating subpar returns on shareholder and company assets.